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The epidermal growth factor receptor (EGFR) pathway hasprovided a new therapeutic target in non-small cell lung
cancer (NSCLC). Two EGFR tyrosine kinase inhibitors
(TKIs) are being used globally as systemic treatment in
advanced NSCLC. In addition, clinical observations with
EGFR TKIS led to the discovery of EGFR activating muta-
tions, which has catalyzed translational research and has
provided new insights into lung cancer biology. Presentations
in the EGFR pathway session included review of molecular
marker data, description of agents and strategies, which could
overcome acquired and inherent EGFR TKI resistance, the
role of HER2 in NSCLC, and discussion of anti-EGFR
monoclonal antibodies.
SUMMARY OF PRESENTATIONS
EGFR Biomarker Review
Dr. Frances Shepherd described identification of pre-
dictive molecular markers related to EGFR TKIs as a riddle
wrapped in the mystery inside an enigma.1–3 An important
clue was provided by molecular data from the IPASS study,
in which previously untreated stage IV NSCLC Asian never
smokers were randomized to a platinum doublet or to ge-
fitinib. Results from this trial showed that patients with EGFR
mutations who received first-line gefitinib had significantly
higher response rates and superior progression free survival
compared with individuals treated with paclitaxel-carbopla-
tin. Conversely, longer progression-free survival was ob-
served in patients with wild-type EGFR treated with chemo-
therapy despite the fact that their clinical features suggested
that they should be more responsive to EGFR TKIs. At this
point, there is no apparent overall survival difference, in the
IPASS trial.
Gefitinib has also been compared with a single cyto-
toxic agent (docetaxel) in a phase III trial (INTEREST) of
patients with previously treated NSCLC. EGFR mutation
analyses were done in a subset of the patients, and the
progression-free survival results were consistent with the
findings in the first-line IPASS study, showing that longer
progression-free survival was associated with gefitinib in
patients with EGFR mutations. Similar to the results from the
IPASS study, there was no difference in overall survival.
Finally, similar results were found in the SATURN trial
in which patients with NSCLC were randomly assigned to
maintenance therapy with erlotinib versus placebo after four
courses of a platinum doublet. The hazard ratio (HR) for
progression-free survival for erlotinib versus placebo was
superior in patients with wild-type EGFR (HR  0.78, p 
0.018), but the difference was more pronounced in patients
with EGFR mutations (HR  0.10, p  0.0001). Patients
treated with maintenance erlotinib survived significantly
longer, but there was no apparent differentiation for patients
with EGFR mutations versus wild-type EGFR.
EGFR copy number defined as fluorescence in situ
hybridization positive activity has been associated with su-
perior survival in patients receiving second- or third-line
erlotinib versus placebo (BR21) and in the erlotinib mainte-
nance trial (SATURN) but not in trials comparing EGFR
TKIs with either a chemotherapy doublet or a similar agent.
Similarly, Kras mutations that have been associated with
significantly lower response rates to EGFR TKIs in some
studies but have not shown a significant predictive value in
relationship to survival for patients treated with EGFR TKIs.
Preliminary studies of serum protein patterns deter-
mined by mass spectroscopy have suggested that this meth-
odology may have predictive value for patients treated with
EGFR TKIs. A confirmatory study is being done on sera
collected from patients treated with erlotinib versus placebo
after one to two previous chemotherapy regiments (BR-21).
In summary, EGFR mutation analysis and not clinical
characteristics should be used in selecting patients for first-
line treatment with an EGFR TKI. In second- and third-line
therapies, there does not seem to be a strong predictor to
select an EGFR TKI over chemotherapy.
Mechanisms of Acquired EGFR TKI Resistance
and Resistance Inhibitors
Patients with 19 or 21 EGFR mutations who responded
or patients who had clinical benefit for 6 months during
treatment with an EGFR TKI and subsequently progressed
are classified as having acquired resistance to EGFR TKIs. At
the time of progression, exon 20 T790M EGFR mutations are
found in a significant number of these tumors. Irreversible
TKIs, which target both EGFR and HER2, have been shown
to have preclinical activity in NSCLCs containing T790M
mutations. In a phase II trial, BIBW-2992, an irreversible
dual EGFR and HER2 inhibitor, was associated with a pro-
gression-free survival of 10.2 months in patients with
NSCLC whose disease had progressed on first-line chemo-
therapy. A phase III first-line NSCLC trial comparing BIBW-
2992 with a platinum doublet will begin patient enrollment
soon. In addition, a phase II/III double-blinded trial compar-
ing BIBW-2992 versus a placebo in patients with NSCLC
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who have failed one or two lines of chemotherapy and either
erlotinib or gefitinib is ongoing.
BMS-690514, another multitargeted erb TKI, which
inhibits vascular endothelial growth factor receptor 2 in
addition to EGFR and HER2, has shown activity in preclin-
ical models. Escalating doses of this agent are being com-
bined with paclitaxel and carboplatin in patients with ad-
vanced NSCLC.
Activation of the Met receptor tyrosine kinase pathway is
another mechanism of resistance to EGFR TKIs. Met pathway
activation can occur through amplification, mutation, increased
protein expression, increased ligand expression, or by mutation.
A variety of ways to inhibit the Met pathway are currently being
tested in phase I/II trials. Met inhibition strategies include
monoclonal antibody targeting the receptor (MetMab) or the
ligand (AMG 102), Met TKIs (ARQ 197 and BMS777607)
multitargeted TKIs (PF02341066—Met and anaplastic lymphoma
kinase), and XL184—Met (vascular endothelial growth factor re-
ceptor2, RET).
Crizotinib (PF2341066) has shown activity in NSCLC,
glioma, prostate cancer, and lymphoma. This agent is cur-
rently being tested in patients with NSCLC whose tumors
might be driven by anaplastic lymphoma kinase transloca-
tions or MET amplification. In addition, escalating doses of
XL184 combined with erlotinib given at a dose of 150 mg
daily or at a dose less than 150 mg daily are being tested in
a phase I study. There are also plans to initiate a randomized
phase II trial in patients with NSCLC whose disease has
progressed after disease control for at least 6 months. Patients
will be randomized to XL184 alone versus XL184 plus
continuation of erlotinib. The monoclonal antibody, METMAB,
is currently being tested in a randomized phase II trial in which
patients receive second- or third-line erlotinib combined with
intravenous (IV) placebo versus erlotinib combined with IV
METMAB.
HER2 in NSCLC
Increased HER2 protein expression is found in approx-
imately 20% of patients with NSCLC and is associated with
worse prognosis. HER2 gene amplification (5%) and HER2
mutations (2%) are relatively uncommon in NSCLC. Several
strategies targeted HER2 in NSCLC have been or are being
tested in NSCLC. Phase II trials that have evaluated the
anti-HER2 monoclonal antibody, trastuzumab combined with
chemotherapy did not seem to superior to chemotherapy
alone. Currently, European investigators are conducting a
phase II trial of BIBW2992 in patients with adenocarcinoma
of the lung containing either EGFR or HER2 mutations.
Anti-EGFR Monoclonal Antibodies
Two first-line phase III trials have compared treatment
with a cisplatin doublet alone versus a cisplatin doublet
combined with cetuximab. In the FLEX trial, a modest
significant improvement in overall survival was observed
(HR  0.87, p  0.044), and in the BMS099 trial, a
nonsignificant trend for improved superior survival was ob-
served in patients treated with chemotherapy combined with
cetuximab (HR  0.89, p  0.17) In the BMS study, tumor
tissue was obtained from a subset of patients and a panel of
molecular markers including Kras mutation, EGFR mutation
in exons 18 to 21, EGFR gene copy number, and EGFR
protein expression were determined. None of these molecular
markers were shown to have predictive value.
Nimotuzumab, a humanized anti-EGFR monoclonal
antibody, is being evaluated in clinical trials. It seems to have
a lower rate of severe rash and hypomagnesaemia compared
with other anti-EGFR monoclonal antibodies. Nimotuzumab
is currently being tested in two randomized phase II trials in
NSCLC. In one trial, patients are receiving 30 to 36 Gy of
chest radiation with placebo versus the same dose of radiation
combined with nimotuzumab 200 mg/wk. Patients with
NSCLC with brain metastases are receiving whole brain
radiation (30 Gy/2 wk) with either IV nimotuzumab 200 mg
or IV placebo given weekly.
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